Chronic Fatigue Meeting Shows Benefits, Hurdles To Patient-Focused Drug Development
Executive Summary
The two-day workshop on chronic fatigue syndrome/myalgic encephalomyelitis elicited extensive, detailed testimony from patients about their symptoms and current treatment that will inform FDA policy, but it also underscored the challenges of explaining FDA’s regulatory processes to the patient community.